Genetic Predictors of Weight Loss and Weight Regain After Intensive Lifestyle Modification, Metformin Treatment, or Standard Care in the Diabetes Prevention Program

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

Citation

Published Version
doi:10.2337/dc11-1328

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:11181096

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
GENETIC PREDICTORS OF WEIGHT LOSS AND WEIGHT REGAIN AFTER INTENSIVE LIFESTYLE MODIFICATION, METFORMIN TREATMENT, OR STANDARD CARE IN THE DIABETES PREVENTION PROGRAM

LINDA M. DELAHANTY, MS, RD1,2
QING PAN, PhD3
KATHLEEN A. JARLONSKI, PhD3
KAROL E. WATSON, MD, PhD4
JEANNE M. McCAFFERY, PhD5
ALAN SHULDINER, MD6

STEVEN E. KAHN, MD, CHB7
WILLIAM C. KNOWLER, MD, DRPH8
JOSE C. FLOREZ, MD, PhD3,2,9,10
PAUL W. FRANKS, MD, MPH, MS11,12
FOR THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*

OBJECTIVE—We tested genetic associations with weight loss and weight regain in the Diabetes Prevention Program, a randomized controlled trial of weight loss–inducing interventions (lifestyle and metformin) versus Placebo.

RESEARCH DESIGN AND METHODS—Sixteen obesity-predisposing single-nucleotide polymorphisms (SNPs) were tested for association with short-term (baseline to 6 months) and long-term (baseline to 2 years) weight loss and weight regain (6 months to study end).

RESULTS—Irrespective of treatment, the Ala12 allele at PPARG associated with short- and long-term weight loss (−0.63 and −0.93 kg/allele, \( P \leq 0.005 \), respectively). Gene–treatment interactions were observed for short-term (LYPLAL1 rs2605100, \( P_{\text{Plifestyle*SNP}} = 0.032 \); GNPDA2 rs10938397, \( P_{\text{Plifestyle*SNP}} = 0.016 \); MTCH2 rs10838738, \( P_{\text{Plifestyle*SNP}} = 0.022 \)) and long-term (NEGR1 rs2815752, \( P_{\text{Plifestyle*SNP}} = 0.028 \); FTO rs9939609, \( P_{\text{Plifestyle*SNP}} = 0.044 \)) weight loss. Three of 16 SNPs were associated with weight regain (NEGR1 rs2815752, BDNF rs6265, PPARG rs1801282), irrespective of treatment. TMEM18 rs6548238 and KCTD15 rs29941 showed treatment-specific effects (\( P_{\text{Plifestyle*SNP}} < 0.05 \)).

CONCLUSIONS—Genetic information may help identify people who require additional support to maintain reduced weight after clinical intervention.

Diabetes Care 35:363–366, 2012

From the 1Diabetes Research Center, Massachusetts General Hospital, Boston, Massachusetts; the 2Department of Medicine, Harvard Medical School, Boston, Massachusetts; the 3Biostatistics Center, George Washington University, Rockville, Maryland; the 4David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California; the 5Weight Control and Diabetes Research Center, The Miriam Hospital and Brown Medical School, Providence, Rhode Island; the 6Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, and Program in Genetics and Genomic Medicine, University of Maryland School of Medicine, Baltimore, Maryland; the 7Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, VA Puget Sound Health Care System and University of Washington, Seattle, Washington; the 8National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona; the 9Center for Human Genetic Research, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; the 10Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts; the 11Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund University Diabetes Center, Skane University Hospital, Malmo, Sweden; and the 12Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts.

Corresponding author: Paul W. Franks, paul.franks@med.lu.se and dppmail@biostat.bsc.gwu.edu.

Received 25 July 2011 and accepted 23 October 2011.

DOI: 10.2337/dc11-1328. Clinical trial reg. no. NCT00004992, clinicaltrials.gov.

*This article contains Supplementary Data online at http://care.diabetesjournals.orglookup/suppl/doi:10.2337/dc11-1328/suppl/

© 2012 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
(Supplementary Table 3) (2). Genetic risk scores were constructed by summing effect alleles (see Supplementary Data) (7). Models are annotated in Supplementary Data.

Primary end points are 1) short-term WL (baseline to 6 months), 2) long-term WL (baseline to 2 years), and 3) average rate of WR (6 months to study end) (range 2–4.5 years). WL analyses included all participants, whereas WR analyses included 1,411 participants who had achieved ≥3% WL at 6 months. Analyses were conducted in the pooled sample adjusting for self-reported ethnicity; sensitivity analyses were repeated in NHW only to rule out population stratification. Unless there was statistical evidence of gene x treatment interactions, data were pooled from the three study arms and models were adjusted for age, sex, ethnicity, treatment, and baseline value for the dependent variable. Where such interactions were observed, treatment-specific genetic effects were estimated. For general linear models assuming additive allele effects (except Pro12Ala, which was coded with Pro12Pro vs. Ala12×), nominal two-sided P values are reported. All P values for the same outcome are adjusted for multiple comparisons, and significant SNP effects are reported (8): for short-term WL, there are three significant SNP*treatment interactions (13 + (3*3) = 22 tests are corrected for); for long-term WL, there are two significant interactions (14 + (3*2) = 20 tests are corrected for); and for WR, there are six significant interactions (10 + (6*3) = 28 tests are adjusted for).

RESULTS—Baseline data are reported in Supplementary Tables 1 and 4. P values for placebo, n = 808; for metformin, n = 409; for lifestyle, n = 1,012).

Table 1—Summary of association data for each of 16 known obesity loci and short-term (6 months) change in weight (kilograms per year), long-term (2 years) change in weight (kilograms per year), and rate of WR from 6 months through trial end (kilograms per year) in the overall DPP cohort and each treatment arm if significant SNP treatment interactions were detected.

<table>
<thead>
<tr>
<th>Nearest gene</th>
<th>SNP</th>
<th>Effect (other) allele</th>
<th>Coefficient (SE)</th>
<th>P value</th>
<th>Coefficient (SE)</th>
<th>P value</th>
<th>Coefficient (SE)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>MC4R</td>
<td>rs17782313</td>
<td>C(T)</td>
<td>0.11 (0.14)</td>
<td>0.433</td>
<td>−0.10 (0.20)</td>
<td>0.633</td>
<td>−0.22 (0.18)</td>
<td>0.241</td>
</tr>
<tr>
<td>FTO</td>
<td>rs9939609</td>
<td>A(T)</td>
<td>−0.12 (0.12)</td>
<td>0.336</td>
<td>0.02 (0.19)</td>
<td>0.899</td>
<td>0.10 (0.18)</td>
<td>0.580</td>
</tr>
<tr>
<td>MTCH2</td>
<td>rs10838738</td>
<td>G(A)</td>
<td>0.11 (0.17)</td>
<td>0.519</td>
<td>0.20 (0.24)</td>
<td>0.408</td>
<td>−0.35 (0.16)</td>
<td>0.034</td>
</tr>
<tr>
<td>NEGR1</td>
<td>rs2815752</td>
<td>A(G)</td>
<td>−0.20 (0.13)</td>
<td>0.130</td>
<td>−0.01 (0.18)</td>
<td>0.934</td>
<td>0.06 (0.21)</td>
<td>0.710</td>
</tr>
<tr>
<td>TMEM18</td>
<td>rs6548238</td>
<td>C(T)</td>
<td>0.01 (0.13)</td>
<td>0.928</td>
<td>0.08 (0.21)</td>
<td>0.710</td>
<td>0.20 (0.20)</td>
<td>0.330</td>
</tr>
<tr>
<td>SHE2B1</td>
<td>rs74986665</td>
<td>T(C)</td>
<td>0.01 (0.13)</td>
<td>0.938</td>
<td>0.08 (0.21)</td>
<td>0.710</td>
<td>0.20 (0.20)</td>
<td>0.330</td>
</tr>
<tr>
<td>SEC16B</td>
<td>rs10913469</td>
<td>C(T)</td>
<td>0.01 (0.13)</td>
<td>0.938</td>
<td>0.08 (0.21)</td>
<td>0.710</td>
<td>0.20 (0.20)</td>
<td>0.330</td>
</tr>
<tr>
<td>BDNF</td>
<td>rs6265</td>
<td>C(T)</td>
<td>−0.04 (0.17)</td>
<td>0.828</td>
<td>0.35 (0.24)</td>
<td>0.140</td>
<td>0.55 (0.21)</td>
<td>0.011</td>
</tr>
<tr>
<td>FAI5M2</td>
<td>rs7138803</td>
<td>A(G)</td>
<td>0.07 (0.13)</td>
<td>0.625</td>
<td>−0.07 (0.19)</td>
<td>0.692</td>
<td>0.12 (0.18)</td>
<td>0.504</td>
</tr>
<tr>
<td>KTCD15</td>
<td>rs29941</td>
<td>G(A)</td>
<td>−0.06 (0.14)</td>
<td>0.639</td>
<td>−0.16 (0.19)</td>
<td>0.404</td>
<td>0.37 (0.27)</td>
<td>0.004</td>
</tr>
<tr>
<td>PPARG</td>
<td>rs1801282</td>
<td>Ala(Pro)</td>
<td>−0.63 (0.22)</td>
<td>0.005</td>
<td>−0.93 (0.31)</td>
<td>0.003</td>
<td>−0.79 (0.27)</td>
<td>0.004</td>
</tr>
<tr>
<td>LYPPL1</td>
<td>rs2605100</td>
<td>G(A)</td>
<td>0.22 (0.20)</td>
<td>0.272</td>
<td>−0.16 (0.18)</td>
<td>0.399</td>
<td>0.41 (0.18)</td>
<td>0.099</td>
</tr>
<tr>
<td>ETV5</td>
<td>rs7647305</td>
<td>C(T)</td>
<td>0.05 (0.14)</td>
<td>0.726</td>
<td>−0.08 (0.20)</td>
<td>0.675</td>
<td>0.17 (0.18)</td>
<td>0.360</td>
</tr>
<tr>
<td>GNPDA2</td>
<td>rs10938397</td>
<td>G(A)</td>
<td>0.08 (0.18)</td>
<td>0.666</td>
<td>0.09 (0.16)</td>
<td>0.577</td>
<td>0.12 (0.20)</td>
<td>0.530</td>
</tr>
<tr>
<td>TFAP2B</td>
<td>rs987237</td>
<td>G(A)</td>
<td>−0.05 (0.15)</td>
<td>0.725</td>
<td>0.15 (0.21)</td>
<td>0.483</td>
<td>0.12 (0.20)</td>
<td>0.530</td>
</tr>
<tr>
<td>MSRA</td>
<td>rs7826222</td>
<td>G(C)</td>
<td>−0.05 (0.16)</td>
<td>0.751</td>
<td>−0.09 (0.23)</td>
<td>0.691</td>
<td>−0.14 (0.21)</td>
<td>0.508</td>
</tr>
<tr>
<td>Treatment-specific SNP effects</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6-Month WL (kg/allele; for lifestyle, n = 1,041; for metformin, n = 1,024; for placebo, n = 1,020)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTCH2</td>
<td>rs10838738</td>
<td>G(A)</td>
<td>−0.12 (0.28)</td>
<td>0.666</td>
<td>−0.02 (0.21)</td>
<td>0.932</td>
<td>0.37 (0.21)</td>
<td>0.079</td>
</tr>
<tr>
<td>LYPPL1</td>
<td>rs2605100</td>
<td>G(A)</td>
<td>0.35 (0.29)</td>
<td>0.234</td>
<td>0.19 (0.22)</td>
<td>0.389</td>
<td>−0.11 (0.22)</td>
<td>0.600</td>
</tr>
<tr>
<td>GNPDA2</td>
<td>rs10938397</td>
<td>G(A)</td>
<td>0.11 (0.26)</td>
<td>0.676</td>
<td>0.12 (0.19)</td>
<td>0.544</td>
<td>0.40 (0.19)</td>
<td>0.038</td>
</tr>
<tr>
<td>2-Year WL (kg/allele; for lifestyle, n = 999; for metformin, n = 1,004; for placebo, n = 1,012)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FTO</td>
<td>rs9939609</td>
<td>A(T)</td>
<td>0.56 (0.36)</td>
<td>0.124</td>
<td>−0.41 (0.27)</td>
<td>0.134</td>
<td>−0.29 (0.26)</td>
<td>0.269</td>
</tr>
<tr>
<td>NEGR1</td>
<td>rs2815752</td>
<td>A(G)</td>
<td>−0.35 (0.37)</td>
<td>0.346</td>
<td>−0.79 (0.29)</td>
<td>0.006</td>
<td>0.19 (0.28)</td>
<td>0.496</td>
</tr>
<tr>
<td>WR rate (kg/year/allele; for lifestyle, n = 808; for metformin, n = 409; for placebo, n = 194)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TMEM18</td>
<td>rs6548238</td>
<td>C(T)</td>
<td>0.62 (0.31)</td>
<td>0.044</td>
<td>0.13 (0.40)</td>
<td>0.745</td>
<td>−0.78 (0.55)</td>
<td>0.158</td>
</tr>
<tr>
<td>KTCD15</td>
<td>rs29941</td>
<td>G(A)</td>
<td>0.50 (0.24)</td>
<td>0.041</td>
<td>−0.17 (0.31)</td>
<td>0.592</td>
<td>−0.36 (0.39)</td>
<td>0.364</td>
</tr>
</tbody>
</table>

Baseline age, sex, and ethnicity are adjusted for in all analyses. Allele effects are in the pooled sample of three treatment groups. The empty cells correspond to cases with significant treatment and allele interactions, and treatment-specific allele effects are estimated. Listed P values are not adjusted for multiple comparisons. Treatment-specific allele effects are reported here when allele effects differ in the three treatment groups.
in Table 1 are obtained from the regressions; however, only SNPs that remain statistically significant after adjusting for multiple comparisons are reported in this section.

**WL**

Short- and long-term WL were greatest in the lifestyle intervention group, and both lifestyle and metformin groups had significantly greater WL than the placebo (control) group (4,5). Irrespective of treatment, the minor Ala12 allele at PPPARG was associated with short- and long-term WL (Table 1). Statistically significant gene–lifestyle interactions were observed for short-term (LYPLAL1 rs2605100; GNPD2 rs10938397; MTCH2 rs10838738) and long-term (NEGR1 rs2815752; FTO rs9939609) WL ($P_{\text{interaction}} < 0.05$).

**WR**

The rate of WR (in kilograms per year) from 6 months to study end was greatest in the lifestyle group and least in the placebo group (Table 1). Those who lost $\geq 3\%$ body weight from baseline to 6 months had a mean (SD) WR of 0.94 ($\pm 4.68$) kg/year. Three of 16 SNPs were associated with WR (NEGR1 rs2815752, BDNF rs6265, PPPARG rs1801282), irrespective of treatment. TMEM18 rs6548238 and KTC15 rs29941 showed treatment-specific effects. In aggregate, the risk alleles associated with WR associated with faster WR (0.274 kg/year/allele [SE = 0.097]; $P = 0.005$), whereas these alleles had no detectable impact on WR in the control group (Supplementary Fig. 1).

Sensitivity analyses performed in NHW participants, who are essentially free of admixture (9), yielded effect estimates of comparable magnitude, indicating that population stratification does not confound our findings (Supplementary Table 5).

**Mediator analyses**

Analyses were also performed assessing putative mediating roles of specific lifestyle factors (details in Supplementary Data). However, none explained a statistically significant amount of variance in the SNP-phenotype relationships.

**CONCLUSIONS**

This is, to our knowledge, the first report of effects of validated obesity-predisposing genotypes on long-term WR after successful intentional WL. We found that three SNPs (NEGR1 rs2815752, BDNF rs6265, PPPARG rs1801282) predicted WR, irrespective of type of WL therapy, two of which (BDNF rs6265; PPPARG Pro12Ala) were robust to correction for multiple hypothesis testing. Two other variants (TMEM18 rs6548238, KTC15 rs29941) interacted with treatment modality to influence WR. We also replicated several associations reported previously with baseline obesity metrics (Supplementary Table 4).

Our WR findings are perhaps most clinically relevant, since these might help target susceptible individuals and thus improve long-term effects of WL interventions. One of few published genetic association studies on WR found that the minor allele at the Pro12Ala locus associated with greater regain 1 year after a 6-month hypocaloric diet intervention ended, also noting reductions in the rate of fat oxidation in Ala12 allele carriers but not in Pro12 homozygotes (10), findings supporting those reported here. A second small study (11) found a similar association between the Pro12Ala genotype and WR, whereas a third small study (12) reported no effect.

Despite plausible mechanisms by which the genetic effects reported here are expressed, we were unable to detect statistically significant mediators. Although the genetic variants we studied may act independently of the selected mediators, it is also possible some of our findings are false-negative, owing to the relatively small sample and indirect measures. Our study is also limited by the absence of information on lifestyle behaviors after 12 months of intervention, which may have hampered the detection of mediators. Finally, the hyperglycemic nature of the DPP cohort may limit generalizability of our findings.

In summary, our findings offer novel insights into the mechanisms influencing the propensity for WR after intentional WL. This information may help target individuals who require additional support to maintain reduced weight in intervention settings.

**Acknowledgments**—This work was funded by R01 DK-072041-02 to J.C.F., K.A.J., and A.S. (P.W.F. and W.C.K. are coinvestigators). P.W.F. was supported by grants from Novo Nordisk, the Swedish Research Council, the Swedish Heart-Lung Foundation, and the Swedish Diabetes Association. S.E.K. is supported in part by the Department of Veterans Affairs. J.C.F. is supported by a Doris Duke Charitable Foundation Clinical Scientist Development Award. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health funded the clinical centers and the Coordinating Center for the design and conduct of the study and the collection, management, analysis, and interpretation of the data. The Southwestern American Indian Centers were supported directly by the NIDDK and the Indian Health Service. The General Clinical Research Center Program, National Center for Research Resources, supported data collection at many of the clinical centers. The Office of Research on Minority Health, the National Institute of Child Health and Human Development, the National Institute on Aging, the Centers for Disease Control and Prevention, Office of Research on Women’s Health, the Department of Veterans Affairs, and the American Diabetes Association funded data collection and provided participant support. This research was also supported, in part, by the intramural research program of the NIDDK. The Henry M. Jackson Foundation provided support services under subcontract with the Coordinating Center.

LifeScan, Health O Meter, Hoechst Marion Roussel, Merck-Medco Managed Care, Merck and Co., Nike Sports Marketing, Slim Fast Foods Co., and Quaker Oats Co. donated materials, equipment, or medicines for concomitant conditions. Bristol-Myers Squibb and Parke-Davis provided medication. McKesson BioServices Corporation and Matthews Media Group provided support services under subcontract with the Coordinating Center. No other potential conflicts of interest relevant to this article were reported.

L.M.D. conceived the analysis, designed the analysis plan, interpreted the results, wrote the manuscript, and provided critical input on the manuscript revisions. Q.P. designed the analysis plan, conducted the statistical analyses, interpreted the results, wrote the manuscript, and provided critical input on the manuscript revisions. K.A.J. designed the analysis plan, conducted the statistical analyses, and provided critical input on the manuscript revisions. S.E.K. and W.C.K. conducted the clinical trial, provided the phenotypic data, and provided critical input on the manuscript revisions. J.C.F. designed the analysis plan, coordinated the genotyping, and provided critical input on the manuscript revisions. P.W.F. conceived the analysis, designed the analysis plan, interpreted the results, wrote the manuscript, and provided critical input on the manuscript revisions and is the guarantor of this article.

The investigators acknowledge the commitment and dedication of all participants in the Diabetes Prevention Program Research Group, without whom this work would not have been possible.

**References**

1. Lindgren CM, Heid IM, Randall JC, et al.; Wellcome Trust Case Control Consortium; Procardis Consortium; Giant Consortium. Genome-wide association scan